comparemela.com
Home
Live Updates
Axsome Therapeutics Announces Results of CRESCENDO Narcoleps
Axsome Therapeutics Announces Results of CRESCENDO Narcoleps
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
77% of narcolepsy type 1 patients continue to experience cataplexy attacks despite being treated 64% of narcolepsy type 1 patients continue to experience excessive daytime sleepiness, as assessed...
Related Keywords
United States ,
United Kingdom ,
Philadelphia ,
Pennsylvania ,
New York ,
British ,
Karl Doghramji ,
Darren Opland ,
Mark Jacobson ,
Nasdaq ,
Axsome Therapeutics Inc ,
Narcolepsy Network ,
World Trade Center ,
Corporate Communications ,
Drug Administration ,
Epworth Sleepiness Scale ,
British Columbia Cognitive Complaints Inventory ,
Characterizing Patient Perspectives ,
Unmet Needs ,
Medical Director ,
Jefferson Sleep Disorders Center ,
Thomas Jefferson University ,
Topline Findings ,
Narcolepsy Symptoms While ,
Neutrality Statement ,
Axsome Therapeutics ,